Drug intelligence / Profile preview

aclaramycin

Development stage: Unknown
Modality: Small Molecules
Administration: Unknown (not Clinically Used; Routes Not Established)

Overview

Aclaramycin is an antibiotic compound belonging to the anthracycline class, structurally related to other antibiotics such as doxorubicin and daunorubicin. It is produced by certain Streptomyces species. Aclaramycin exhibits antibacterial activity, particularly against Gram-positive bacteria, by inhibiting bacterial DNA synthesis through intercalation into DNA and inhibition of topoisomerase II (DNA gyrase). Its primary use has been in research settings rather than clinical practice, and it is not widely marketed or approved for human therapeutic use.

Targets

TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)

Beyond the preview

Go deeper on aclaramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aclaramycin.

Explore the full profile